Research guide · Recovery & Repair
TB500 — research protocol
Thymosin Beta-4 fragment studied for tissue repair and angiogenesis studies.
This guide summarizes study areas and sources associated with the compound. BioPeptideX does not convert experimental information into a clinical regimen or recommend an individual dose, frequency, route or duration.
Catalog presentations
Concentration table
Mathematical reference only; this is not a dosing recommendation.
Research areas
- Thymosin Beta-4 fragment
- Tissue repair
- 99% HPLC purity
Most-cited research protocols
Educational information based on research protocols and literature; it does not replace guidance from a healthcare professional.
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, primarily used in community research protocols. It is not FDA-approved and is sold for research purposes only.
| Dose | Frequency | Duration | Route | |
|---|---|---|---|---|
| Loading phase (Load + Maintenance) | ~2-2.5 mg | Twice weekly | Weeks 1-6 | Subcutaneous |
| Maintenance phase (Load + Maintenance) | ~2-2.5 mg | Once weekly | Weeks 7-12 | Subcutaneous |
| Front-loading (Acute Injury Window) | ~2-2.5 mg | Every 2-3 days | Weeks 1-2 | Subcutaneous |
| Taper (Acute Injury Window) | ~2-2.5 mg | Once weekly | Weeks 3-8 | Subcutaneous |
Cycle: Common research-use cycles are 4-12 weeks, often followed by an off period of 4-8 weeks.
Benefits and research observations: Some research-use planners describe perceived recovery improvements within the first 2-4 weeks. Monitor injection site condition, sleep quality, cycle adherence, and any new or unusual symptoms.
Handling and storage
Store unreconstituted product according to its label and maintain the cold chain where applicable. After any preparation, follow only validated instructions for the specific product and diluent. Do not use if packaging is damaged or the solution shows particles or unexpected changes.
Warnings
Do not use this page for self-diagnosis or self-medication. Pregnancy, breastfeeding, minors, cancer history, allergies, active disease and concurrent treatments require individual professional evaluation.
Published sources
- 1.Goldstein AL, et al. Ann NY Acad Sci, 2010.
- 2.Crockford D, et al. Ann NY Acad Sci, 2010.